Lyxumia^®

Two presentations of Lyxumia have been discontinued. Any Lyxumia currently in the market can continue to be used. This is not due to any safety issues and the DHSC have been informed.

Which presentations are being affected?
The following presentations will be discontinued, with no alternative presentations being available:

• Lyxumia 10 micrograms/0.2ml solution for injection 3ml filled pen (end of supply June 2022)
• Lyxumia Treatment initiation pack 10/20mcg (end of supply June 2022)

Lyxumia 20 micrograms/0.2ml solution for injection 3ml pens will not be impacted by this discontinuation.

What does this mean for patients?

It will no longer be an option to start your patients on treatment with Lyxumia. Alternative treatments should be considered for patients under the supervision of their HCP. The discontinuation of these presentations is not as a result of any safety concern. Lyxumia which is still in the market can continue being used until the expiry date.